What we do Roopa Industries Ltd manufactures bulk drugs, drug intermediates, and nutraceuticals including active pharmaceutical ingredients like Fluconazole and Sildenafil Citrate. |
Founded in 1,985 |
Market share A recognized player in the Indian pharmaceutical intermediates and bulk drugs sector with exports to Germany, Netherlands, and Sri Lanka. |
Problem solved Provides critical pharmaceutical ingredients and nutraceuticals addressing needs in antibiotics, arthritis treatment, and specialty chemicals. |
Top clients or who we serve Supplies pharmaceutical companies and specialty chemical manufacturers; operates primarily B2B with some nutraceutical indirect consumers. |
Key management Tumbalam Gooty Raghavendra (Managing Director), Vishnu Vardhan Bhimaneni (CEO), Indani Venkata Lakshmi (Company Secretary). |
Our journey and innovations Evolved from granite manufacturing to pharmaceuticals since 1998; expertise in handling hazardous chemical processes and key product innovations like Triphenyl Phosphine. |
Where we operate India-based operations with exports mainly to Germany, Netherlands, and Sri Lanka. |
Top products or what we offer Key products include Triphenyl Phosphine, Fluconazole, Sildenafil Citrate, Losartan Potassium, and various Glucosamine salts. |
Top brands Triphenyl Phosphine (#1 in organic synthesis applications), Glucosamine (nutraceutical with growing arthritis applications). |
Raw materials needed Chemical raw materials for bulk drugs and intermediates; natural sources for glucosamine extraction. |
Raw materials supplier Suppliers of specialty chemicals and natural extract providers; specific names not disclosed. |
Recurring vs cyclical contribution Revenue is largely recurring from ongoing pharmaceutical ingredient contracts with some cyclical variability. |
Our industry position Strong technical expertise in hazardous manufacturing, niche presence in pharmaceutical intermediates and nutraceuticals. |
Financial highlights FY 2024-25 revenue ₹122.98 crore; profit after tax ₹2.03 crore; consistent growth over previous year. |
Geographical revenue split Domestic revenue ₹67.7 crore (approx 96%), exports ₹2.7 crore (approx 4%). |
Order book - |
Whats driving growth Stabilization and expansion of Triphenyl Phosphine production, growing nutraceutical demand, and export market development. |
Our future plans Enhance core TPP production capacity, improve operational efficiencies, and strengthen export footprint. |
Our green promise Focuses on safe hazardous chemical manufacturing and compliance; no specific ESG initiatives detailed. |
Our people and values Employs 51 people, committed to safety, professionalism, and employee engagement. |
Key challenges ahead Managing hazardous processes safely, competitive pharmaceutical market pressures, and regulatory compliance. |
Interesting facts Originally a granite company transformed into a specialized pharmaceutical chemical manufacturer since 1998. |
Risks and strategy Mitigates risk via robust internal controls, compliance adherence, and continual board oversight. |
